Table 2.
Paper | Design | Study population | Diagnostic test for mimicking disease | Reference standard for mimicking disease* | Time interval | Sens, % (95% CI)† |
Spec, % (95% CI)† |
RoB |
Fan, 201617 | CS | Established RA (n=279), with final diagnosis:
|
Fibromyalgia Rapid Screening Tool ≥5 (/6) | FM according to:
|
Concurrent | 71 (42 to 92) 83 (51 to 95) |
84 (79 to 89) 88 (83 to 91) |
H |
Ghib, 2018‡18 | CC | Established RA (n=20):
|
MicroRNA-143 >1.0 | FM: NR | NR | 90 | 70 | H |
Salaffi, 201820 | CS | Established RA (n=292), with final diagnosis:
|
Derived DAS28 patient-reported components (DAS28-P)* >0.6312 *(0.56×√TJC +0.014× GH)/DAS28 |
FM according to ACR 2010 criteria119 | NR | 81 (67 to 92) | 80 (75 to 85) | H |
Sato, 201219 | CS | Established RA (n=118), with final diagnosis:
|
Procalcitonin ≥0.5 ng/mL Procalcitonin ≥0.2 ng/mL WCC >8500/m3 CRP ≥0.3 mg/dL ESR >15 mm/hour Procalcitonin ≥0.5 ng/mL+WCC >8500/m3 |
Bacterial Infection: symptoms, bacterial culture tests, imaging studies, and response to antibiotic therapy | Within period of hospital admission | 26 34 66 70 98 21 |
98 89 59 5 9 1 |
L |
*A clinical diagnosis according to a rheumatologist was deemed as the appropriate reference standard.
†95% CI, if reported.
‡Abstract.
ACR, American College of Rheumatology; CC, case control; CRP, C reactive protein; CS, cross-sectional; DAS28, Disease Activity Score Assessing 28 joints; ESR, erythrocyte sedimentation rate; FM, fibromyalgia; GH, global health; H, high (red); L, low (green); NR, not reported; RA, rheumatoid arthritis; RoB, risk of bias; sens, sensitivity; spec, specificity; TJC, tender joint count; VAS, Visual Analogue Scale; WCC, white cell count.;